A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Sponsor

Amgen (Industry)

Overall Status

Completed

CT.gov ID

NCT00189501

Collaborator

(none)

1,000

Enrollment

Study Details

Study Description

Brief Summary

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

Condition or Disease	Intervention/Treatment	Phase
Nephrology	Drug: Sensipar®

Study Design

Study Type:

Observational

Time Perspective:

Prospective

Official Title:

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Study Start Date :

Dec 1, 2004

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

3 month history of Stage 4 or Stage 5 CKD
A PTH value within 3 months of enrollment
If relevant, completion of Sensipar® study prior to enrolling in Registry Exclusion